Related Experiment Video
Updated: Dec 28, 2025
10:15
Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
Published on: November 10, 2021
2.1K
PDGFR-β and kidney fibrosis
1IIS-Fundacion Jimenez Diaz, Department of Medicine, School of Medicine, Universidad Autonoma de Madrid, Madrid, Spain.
EMBO Molecular Medicine
|February 20, 2020
Summary
Chronic kidney disease (CKD) is a growing global health threat. Targeting kidney fibrosis, a key feature of CKD, offers new diagnostic and therapeutic strategies for earlier detection and treatment.
Area of Science:
- Nephrology
- Pathology
- Biomedical Research
Background:
- Chronic kidney disease (CKD) is a rapidly increasing cause of mortality worldwide, with projections placing it among the top five causes of death by 2040.
- Current diagnostic and management strategies for CKD have significant limitations, necessitating novel approaches.
- Even early stages of CKD, with preserved renal function, are linked to a higher risk of premature mortality.
Discussion:
- Kidney fibrosis, characterized by inflammation and parenchymal cell loss, is the primary histopathological feature of CKD.
- Fibrosis presents a promising target for developing diagnostic tools for earlier CKD detection.
- Targeting kidney fibrosis could offer therapeutic avenues to decelerate CKD progression or even induce regression.
Key Insights:
- Early diagnosis of CKD is crucial due to the association with increased mortality risk even in early stages.
- Kidney fibrosis is a central pathological process in CKD.
- Fibrosis represents a viable target for both diagnostic and therapeutic advancements in CKD management.
Outlook:
- Development of novel diagnostic tests based on kidney fibrosis markers.
- Exploration of anti-fibrotic therapies to slow or reverse CKD progression.
- Improved patient outcomes through earlier CKD detection and intervention targeting fibrosis.
